News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE Immunotherapeutics reports unaudited full year 2025 financial results and Q1 2026 cash position. Cash runway unchanged till early Q4 2026. Filing of 2025 Registration Document postponed to May 28, 2026